Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | F13A1 | P00488 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 2/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.51 |
| ▸ | EDNRA | P25101 | 1/20 | 0.49 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437935 | 0.85 | DPP3 (0.58) | DPP3CAPN1CTSBCXCR4CXCL8 | |
| SCHEMBL30018500 | 0.84 | DPP3 (0.67) | DPP3CXCR4CXCL8CCKBR | |
| SCHEMBL29437939 | 0.84 | CAPN1 (0.60) | DPP3CAPN1CTSBCXCR4 | |
| SCHEMBL29437937 | 0.83 | CAPN1 (0.63) | DPP3CAPN1CTSBCXCR4CXCL8 | |
| SCHEMBL29754415 | 0.83 | CXCR4 (0.61) | CXCR4CXCL8NPY1RNPY2RNPY4R | |
| SCHEMBL30224116 | 0.83 | CAPN1 (0.64) | DPP3CAPN1CTSBCXCR4CXCL8 | |
| SCHEMBL29437938 | 0.82 | CAPN1 (0.61) | DPP3CAPN1CTSBF13A1TGM2 | |
| SCHEMBL19787869 | 0.82 | DPP3 (0.69) | DPP3CAPN1CTSB | |
| SCHEMBL31235881 | 0.82 | DPP3 (0.57) | DPP3CAPN1CTSBF13A1TGM2 | |
| SCHEMBL30477480 | 0.82 | CAPN1 (0.65) | DPP3CAPN1CTSBCXCR4CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2026-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | VIP, ARGLU1, PELP1 | DPP3 84/4885CAPN1 971/4885CTSB 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.